FR17C0007I2 - Procédé d'obtention du NGF-bêta biologiquement actif - Google Patents

Procédé d'obtention du NGF-bêta biologiquement actif

Info

Publication number
FR17C0007I2
FR17C0007I2 FR17C0007C FR17C0007C FR17C0007I2 FR 17C0007 I2 FR17C0007 I2 FR 17C0007I2 FR 17C0007 C FR17C0007 C FR 17C0007C FR 17C0007 C FR17C0007 C FR 17C0007C FR 17C0007 I2 FR17C0007 I2 FR 17C0007I2
Authority
FR
France
Prior art keywords
ngf
biologically active
beta
preparation
proform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C0007C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wacker Chemie AG
Original Assignee
Wacker Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wacker Chemie AG filed Critical Wacker Chemie AG
Publication of FR17C0007I1 publication Critical patent/FR17C0007I1/fr
Application granted granted Critical
Publication of FR17C0007I2 publication Critical patent/FR17C0007I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR17C0007C 1998-10-09 2017-09-27 Procédé d'obtention du NGF-bêta biologiquement actif Active FR17C0007I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119077A EP0994188B1 (de) 1998-10-09 1998-10-09 Verfahren zur Gewinnung von aktivem Beta-NGF

Publications (2)

Publication Number Publication Date
FR17C0007I1 FR17C0007I1 (fr) 2017-11-17
FR17C0007I2 true FR17C0007I2 (fr) 2018-11-09

Family

ID=8232766

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C0007C Active FR17C0007I2 (fr) 1998-10-09 2017-09-27 Procédé d'obtention du NGF-bêta biologiquement actif

Country Status (14)

Country Link
US (2) US8318671B1 (ko)
EP (1) EP0994188B1 (ko)
JP (2) JP4634611B2 (ko)
KR (1) KR100593831B1 (ko)
AT (1) ATE257514T1 (ko)
AU (1) AU765810B2 (ko)
BR (1) BR9914393B1 (ko)
CA (1) CA2346257C (ko)
DE (1) DE59810555D1 (ko)
ES (1) ES2213861T3 (ko)
FR (1) FR17C0007I2 (ko)
NL (1) NL300894I2 (ko)
WO (1) WO2000022119A1 (ko)
ZA (1) ZA200102780B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
US9617322B2 (en) * 2011-12-19 2017-04-11 Wacker Chemie Ag ProNGF mutants and uses thereof in the production of beta-NGF
CN103880943A (zh) * 2014-01-20 2014-06-25 厦门北大之路生物工程有限公司 一种rhNGF成熟肽的制备方法
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业（上海）股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
EP3406259A1 (en) 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
CN108467428A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 一种清除rhNGF中N端截短及异常变异体的方法
US20210079053A1 (en) 2018-04-27 2021-03-18 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
AU2019343514A1 (en) 2018-09-17 2021-04-15 Chiesi Farmaceutici S.P.A. Agent for treatment of dermatological disorders
CN110093394B (zh) * 2019-05-10 2023-10-03 重庆科润生物医药研发有限公司 一种蛋白包涵体及重组人β-神经生长因子的制备方法
MX2022002833A (es) 2019-09-17 2022-04-06 Chiesi Farm Spa Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos.
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en) 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf isoform for use in the treatment of ocular pathologies
AU2022258342A1 (en) 2021-04-13 2023-11-02 Dompé Farmaceutici S.P.A. Treatment of neuropathic corneal pain with ngf
EP4311554A1 (en) 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology
EP4316505A1 (en) 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en) 2022-09-23 2024-03-27 Dompe' Farmaceutici S.P.A. Ngf for the treatment of spasticity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5683894A (en) 1988-04-29 1997-11-04 University Of California Recombinant nerve growth factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
AU3564595A (en) * 1994-09-12 1996-03-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Biologically active molecules derived from neurotrophins
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
CA2257122C (en) 1996-06-11 2004-04-06 Boehringer Mannheim Gmbh Method of activating denatured protein
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF

Also Published As

Publication number Publication date
DE59810555D1 (de) 2004-02-12
US20100203589A1 (en) 2010-08-12
FR17C0007I1 (fr) 2017-11-17
JP4634611B2 (ja) 2011-02-16
ES2213861T3 (es) 2004-09-01
KR20010083900A (ko) 2001-09-03
AU1034800A (en) 2000-05-01
KR100593831B1 (ko) 2006-06-28
EP0994188B1 (de) 2004-01-07
BR9914393A (pt) 2001-06-26
JP5275306B2 (ja) 2013-08-28
CA2346257A1 (en) 2000-04-20
JP2010280717A (ja) 2010-12-16
US8501439B2 (en) 2013-08-06
AU765810B2 (en) 2003-10-02
BR9914393B1 (pt) 2021-06-22
ATE257514T1 (de) 2004-01-15
WO2000022119A1 (de) 2000-04-20
ZA200102780B (en) 2002-07-04
CA2346257C (en) 2005-03-01
NL300894I2 (nl) 2018-02-01
JP2002527062A (ja) 2002-08-27
EP0994188A1 (de) 2000-04-19
US8318671B1 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
FR17C0007I2 (fr) Procédé d'obtention du NGF-bêta biologiquement actif
DE3477810D1 (en) Polypeptide and protein products, and processes for their production and use
PT1305056E (pt) Enxerto osseo sintetico poroso e processo para a sua fabricacao
DE60037450D1 (de) Funf-helix protein
NO20014364L (no) Ny cytokin-zalphall-ligand
WO2000061768A3 (en) Preparation of biologically active molecules
ES2187782T3 (es) Procedimiento para la produccion de polipeptidos.
EA200100834A1 (ru) Способ получения 5-цианофталида
ES2155278T3 (es) Procedimiento para producir fibra de poliester y la fibra de poliester obtenida por el mismo.
AR026063A1 (es) Metodo para la preparacion de 5-carboxiftalida.
WO2002044203A3 (de) Herstellung von rekombinantem bmp-2
ATE419228T1 (de) Herstellung von fluoromethyl-2,2,2-trifluoro-1- (trifluoromethyl)ethylether
IL153943A0 (en) SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY
CA2257122A1 (en) Method of activating denatured protein
IT1292130B1 (it) Processo per la preparazione dell'acido 1,4,7,10-tetraazaciclododecan -1,4,7-triacetico e suoi derivati
WO2003051927A3 (en) Production of f(ab')2 fragments in mammalian cells
PL343316A1 (en) Process for producing 5-hydroxybenzo[b]thiophene-3-carboxylic acid derivatives
AR033979A1 (es) Metodo para preparar un polipeptido il-18 fisiologicamente activo
DE69914327D1 (de) Biologisch aktive mikrodispersionszusammensetzung
IT1298267B1 (it) Procedimento per la preparazione dell'acido (s)-2-acetiltio-3-fenil- propionico e dei suoi sali
EA200201003A1 (ru) Аморфная модификация торасемида
BRPI9913018A (pt) processo para a preparação de somatotropina ativa a partir de corpúsculos de inclusão.
ES2184033T3 (es) Proceso para la preparacion de acido 5-bromo-2-fluorobencenoborico.
ATE205529T1 (de) Reninaktive substanz enthaltend humanes prorenin und antikörper gegen das prorenin profragment
CA2359256A1 (en) Propagation of bovine coronavirus in chinese hamster ovary cells